Mainz Biomed N.V. (NASDAQ: MYNZ)
$0.42
-0.0086 ( -1.99% ) 765.0K
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
Market Data
Open
$0.42
Previous close
$0.43
Volume
765.0K
Market cap
$9.36M
Day range
$0.40 - $0.45
52 week range
$0.32 - $4.89
SEC Fillings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 6-k | Quarterly Reports | 3 | May 31, 2024 |
| 6-k | Quarterly Reports | 6 | Apr 24, 2024 |
| 6-k | Quarterly Reports | 3 | Apr 19, 2024 |
| 20-f | Annual reports | 121 | Apr 09, 2024 |
| 6-k | Quarterly Reports | 15 | Feb 23, 2024 |
| 6-k | Quarterly Reports | 93 | Nov 16, 2023 |
| 6-k | Quarterly Reports | 9 | Nov 15, 2023 |
| 6-k | Quarterly Reports | 2 | Nov 13, 2023 |
| 6-k | Quarterly Reports | 2 | Sep 13, 2023 |
| 6-k | Quarterly Reports | 86 | Aug 15, 2023 |